Loading…
Employees: 3,108
Size Solara Active Pharma Sciences (SOLARA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $323M, the 1026th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹633.70 on 6 Nov 2026.
Performance Over six months the shares gained 23.1%, against -25.9% for the median peer and 0.0% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 27.3% over the last twelve months (peer median -4.4%); the operating margin is 8.4% (peer median 4.9%).
Valuation It trades at 20.2× forward earnings against a peer median of 16.1× (2nd most expensive of 4).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +41 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.4 points below its cost of capital (16.4% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹15.4B | ₹13.6B | ₹12.7B | ₹12.7B | ₹14.3B |
| Revenue growth | — | +7% | 0% | -11% | — |
| Gross profit | ₹4.12B | ₹1.94B | ₹1.86B | -₹1.30B | ₹1.25B |
| EBITDA | ₹2.34B | ₹1.80B | ₹1.93B | -₹2.83B | ₹1.19B |
| Net income | ₹369M | -₹74.1M | ₹5.40M | -₹5.67B | -₹222M |
| Free cash flow | n/a | ₹88.8M | ₹605M | -₹316M | -₹352M |
| Capital expenditure | n/a | ₹528M | ₹399M | ₹411M | ₹1.11B |
| Total debt | ₹5.91B | ₹6.87B | ₹7.96B | ₹10.1B | ₹10.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SOLARA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -11.0% | 5th highest of 20 |
| 6-month return | +23.1% | -25.9% | 2nd highest of 20 |
| Distance from 52-week high | -18.1% | -45.8% | 2nd highest of 20 |
| Revenue growth (TTM) | +27.3% | -4.4% | 2nd highest of 19 |
| Operating margin | 8.4% | 4.9% | 5th highest of 20 |
| Forward P/E | 20.2× | 16.1× | 2nd most expensive of 4 |
| Growth the price implies (Req g, 7 yrs) | 37.7% | 5.7% | 2nd most demanding of 14 |
| Growth delivered (Del g) | -3.2% | +0.6% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | +40.8 pp | +7.8 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -11.4 pp | -5.0 pp | 6th lowest of 19 |
| EV / EBITDA | 15.3× | 8.0× | 3rd most expensive of 7 |
| Net debt / EBITDA | 2.2× | 1.0× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 20.2× | 37.7% | -3.2% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | n/a | 2.5% | -4.9% |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | n/a | n/a | n/a |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | n/a | 15.1% | +7.3% |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | n/a | 31.5% | +7.4% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | n/a | 22.5% | +0.5% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | n/a | 2.7% | +2.3% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | n/a | 5.7% | -0.3% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | n/a | n/a | n/a |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | n/a | -10.4% | +10.3% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 12.0× | -16.7% | +5.4% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | n/a | 58.0% | -12.8% |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 23.4× | 5.5% | +62.1% |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | n/a | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | n/a | 28.5% | -6.4% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | n/a | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 16.1× | -0.1% | -13.7% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | n/a | 10.1% | +0.6% |